Interest in the role of the cannabis derivative cannabidiol (CBD) in the wellness market has continued to rise, despite some concerns over safety and ongoing regulatory issues over its use. Its current growth spurt in new product activity started in 2018 and continued through 2019 and 2020 amid rising consumer awareness.

Open Book Extracts and Case Western Reserve University School of Medicine have entered into an agreement to explore the mechanistic effects of cannabinoids on brain cell functions.

Willow Biosciences Inc. has undertaken two initiatives to improve the understanding of cannabigerol (CBG), the company’s first commercial cannabinoid slated for production in the first quarter of 2021.

Founded by Chris Hetherington, Peels has secured a $4 million investment from KarpReilly, LLC, a Greenwich, Connecticut-based private investment firm.

Treehouse will serve as a center of scientific excellence and product development for Next Frontier Brands and will manufacture the company's growing portfolio of hemp-based wellness products.

Charlotte's Web Holdings, Inc.’s CW Labs science division and the University at Buffalo's Center for Integrated Global Biomedical Sciences are collaborating to advance hemp cannabinoid science through a research program that provides a better understanding of the therapeutic uses and safety of cannabinoids.

This THC-free cannabinol (CBN) isolate is refined and purified through multi-phase distillation.

New research, published in the “Journal of Agricultural and Food Chemistry,” suggests a product’s matrix can impact a lab’s ability to precisely test for cannabinoid content.